A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.
(2016) In RMD Open 2(1). p.000133-000133- Abstract
- Treatment with tumour necrosis factor (TNF) blockers, once started as therapy for rheumatoid arthritis (RA), is usually continued indefinitely. The aim of this trial was to assess the possibility of discontinuing treatment with adalimumab (ADA) while maintaining remission in patients with RA with established disease in stable remission on combination therapy with ADA and methotrexate (MTX).
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8573144
- author
- Chatzidionysiou, Katerina ; Turesson, Carl LU ; Teleman, Annika ; Knight, Ann ; Lindqvist, Elisabet LU ; Larsson, Per ; Cöster, Lars ; Forslind, Kristina LU ; van Vollenhoven, Ronald and Heimbürger, Mikael
- organization
- publishing date
- 2016
- type
- Contribution to journal
- publication status
- published
- subject
- in
- RMD Open
- volume
- 2
- issue
- 1
- pages
- 000133 - 000133
- publisher
- BMJ Publishing Group
- external identifiers
-
- pmid:26819752
- pmid:26819752
- scopus:84988447917
- ISSN
- 2056-5933
- DOI
- 10.1136/rmdopen-2015-000133
- language
- English
- LU publication?
- yes
- id
- b2878c4b-49eb-45b5-9d29-dcce21d61a17 (old id 8573144)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/26819752?dopt=Abstract
- date added to LUP
- 2016-04-04 09:33:39
- date last changed
- 2022-03-31 03:22:18
@article{b2878c4b-49eb-45b5-9d29-dcce21d61a17, abstract = {{Treatment with tumour necrosis factor (TNF) blockers, once started as therapy for rheumatoid arthritis (RA), is usually continued indefinitely. The aim of this trial was to assess the possibility of discontinuing treatment with adalimumab (ADA) while maintaining remission in patients with RA with established disease in stable remission on combination therapy with ADA and methotrexate (MTX).}}, author = {{Chatzidionysiou, Katerina and Turesson, Carl and Teleman, Annika and Knight, Ann and Lindqvist, Elisabet and Larsson, Per and Cöster, Lars and Forslind, Kristina and van Vollenhoven, Ronald and Heimbürger, Mikael}}, issn = {{2056-5933}}, language = {{eng}}, number = {{1}}, pages = {{000133--000133}}, publisher = {{BMJ Publishing Group}}, series = {{RMD Open}}, title = {{A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.}}, url = {{http://dx.doi.org/10.1136/rmdopen-2015-000133}}, doi = {{10.1136/rmdopen-2015-000133}}, volume = {{2}}, year = {{2016}}, }